Positive Long-Term VenoValve® First-in-Human Data Presented at 34th Annual Meeting of the American Venous Forum

– First-in-Human VenoValve recipients continue to benefit from VenoValve at average of 30 months post-surgery – No venous ulcer recurrences, relapses of CVI, or safety issues – Improvements in average Reflux, disease manifestations (VCSS), and pain (VAS) endpoints continue to be encouraging

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.


Cancel reply

Please enter your comment!
Please enter your name here